Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Regional Referral Headache Centre, Sant'Andrea Hospital, Via di Grottarossa, 1035, 00189, Rome, Italy.
J Headache Pain. 2018 Jan 10;19(1):2. doi: 10.1186/s10194-017-0830-2.
Migraine remains one of the biggest clinical case to be solved among the non-communicable diseases, second to low back pain for disability caused as reported by the Global Burden of Disease Study 2016. Despite this, its genetics roots are still unknown. Its evolution in chronic forms hits 2-4% of the population and causes a form so far defined Medication Overuse Headache (MOH), whose pathophysiological basis have not been explained by many dedicated studies. The Global Burden of Disease Study 2016 has not recognized MOH as independent entity, but as a sequela of Chronic Migraine. This concept, already reported in previous studies, has been confirmed by the efficacy of OnabotulinumtoxinA in Chronic Migraine independently from the presence of MOH. The consistency of the current definitions of both Medication Overuse Headache and Chronic Migraine itself might be re-read on the basis of new evidences.
偏头痛仍然是非传染性疾病中最大的临床难题之一，仅次于全球疾病负担研究 2016 年报告的腰痛导致的残疾。尽管如此，其遗传根源仍不清楚。其在慢性形式中的演变影响了 2-4%的人口，并导致了一种迄今为止被定义为药物过度使用性头痛（MOH）的形式，许多专门的研究尚未解释其病理生理学基础。全球疾病负担研究 2016 年并未将 MOH 视为独立实体，而是将其视为慢性偏头痛的后遗症。这一概念在以前的研究中已有报道，并得到了肉毒毒素 A 在慢性偏头痛中的疗效的证实，而不管是否存在 MOH。基于新的证据，药物过度使用性头痛和慢性偏头痛本身的当前定义的一致性可能需要重新审查。
